Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Study of CN128 in Thalassemia Patients
NCT03935633Phase 1Completed
- Sponsor
- Hangzhou Zede Pharmaceutical Technology
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Tiralos in thalassemia (2 arms), sponsored by Hangzhou Zede Pharmaceutical Technology. Primary endpoints: Incidence rate of adverse events, Vital signs (Pulse, Respiration, Blood pressure, Temperature) and 7 more. Started Dec 2018; status: completed.
02
Drugs
Tiralos
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT03935633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935633.